GlobeNewswire: InspireMD, Inc. Contains the last 10 of 113 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:50:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852210/0/en/InspireMD-Announces-Abstract-of-One-Year-Follow-Up-Results-from-the-C-GUARDIANS-U-S-Investigational-Device-Exemption-IDE-Clinical-Trial-Accepted-for-Presentation-at-LINC-2024.html?f=22&fvtc=4&fvtv=42453InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 20242024-03-26T11:00:00Z<![CDATA[TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.]]>https://www.globenewswire.com/news-release/2024/03/06/2841249/0/en/InspireMD-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=42453InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update2024-03-06T12:00:00Z<![CDATA[- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 -]]>https://www.globenewswire.com/news-release/2024/02/28/2836813/0/en/InspireMD-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Corporate-Business-Update-on-Wednesday-March-6th.html?f=22&fvtc=4&fvtv=42453InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th2024-02-28T12:00:00Z<![CDATA[-Conference call and webcast to be held at 8:30 a.m. EST-]]>https://www.globenewswire.com/news-release/2024/02/12/2827400/0/en/InspireMD-Appoints-Principal-Investigators-for-C-GUARDIANS-II-Clinical-Trial-of-the-SwitchGuard-Neuroprotection-System.html?f=22&fvtc=4&fvtv=42453InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System2024-02-12T12:00:00Z<![CDATA[Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform]]>https://www.globenewswire.com/news-release/2024/01/31/2820960/0/en/InspireMD-Receives-CE-Mark-Recertification-Under-EU-s-New-Medical-Device-Regulation-MDR-Regulatory-Framework.html?f=22&fvtc=4&fvtv=42453InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework2024-01-31T12:00:00Z<![CDATA[TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework. MDR replaced the previous MDD framework, which had governed the approval and marketing of medical devices in the EU until May of 2021.]]>https://www.globenewswire.com/news-release/2024/01/03/2803154/0/en/InspireMD-Announces-Appointment-of-Medical-Technology-Executive-Pete-Ligotti-as-Executive-Vice-President-and-General-Manager-of-North-America.html?f=22&fvtc=4&fvtv=42453InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America2024-01-03T12:00:00Z<![CDATA[Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team]]>https://www.globenewswire.com/news-release/2023/12/20/2799146/0/en/InspireMD-Announces-Issuance-of-Key-U-S-Patent-Covering-Its-SwitchGuard-Neuroprotection-System.html?f=22&fvtc=4&fvtv=42453InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System2023-12-20T12:00:00Z<![CDATA[Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke]]>https://www.globenewswire.com/news-release/2023/11/27/2786025/0/en/InspireMD-Announces-Strategic-Agreement-with-Jacobs-Institute-to-Execute-Early-Feasibility-Study-of-CGuard-EPS-for-the-Treatment-of-Acute-Stroke-Patients-with-Tandem-Lesions.html?f=22&fvtc=4&fvtv=42453InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions2023-11-27T12:00:00Z<![CDATA[Study to enroll 15 acute stroke patients across three U.S. sites Study to enroll 15 acute stroke patients across three U.S. sites]]>https://www.globenewswire.com/news-release/2023/11/06/2773922/0/en/InspireMD-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=42453InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-06T12:00:00Z<![CDATA[- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –]]>https://www.globenewswire.com/news-release/2023/11/02/2772201/0/en/InspireMD-to-Participate-in-Upcoming-November-Investor-Conferences.html?f=22&fvtc=4&fvtv=42453InspireMD to Participate in Upcoming November Investor Conferences2023-11-02T12:00:00Z<![CDATA[TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:]]>